Cocrystal Pharma, Inc. (NASDAQ:COCP) Sees Large Decline in Short Interest

Cocrystal Pharma, Inc. (NASDAQ:COCPGet Rating) saw a significant decrease in short interest in May. As of May 15th, there was short interest totalling 58,200 shares, a decrease of 58.4% from the April 30th total of 139,900 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 279,000 shares, the days-to-cover ratio is presently 0.2 days.

Shares of NASDAQ:COCP traded up $0.02 during mid-day trading on Friday, reaching $0.42. 355,783 shares of the stock were exchanged, compared to its average volume of 363,482. The company has a market cap of $40.45 million, a P/E ratio of -2.59 and a beta of 1.13. Cocrystal Pharma has a one year low of $0.37 and a one year high of $1.49. The stock’s 50 day simple moving average is $0.49 and its 200-day simple moving average is $0.59.

Cocrystal Pharma (NASDAQ:COCPGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). As a group, research analysts forecast that Cocrystal Pharma will post -0.16 EPS for the current fiscal year.

Hedge funds have recently bought and sold shares of the business. Barclays PLC grew its stake in Cocrystal Pharma by 248.5% in the third quarter. Barclays PLC now owns 26,665 shares of the company’s stock valued at $28,000 after purchasing an additional 19,014 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Cocrystal Pharma by 5,155.0% in the fourth quarter. JPMorgan Chase & Co. now owns 59,959 shares of the company’s stock valued at $39,000 after purchasing an additional 58,818 shares in the last quarter. Two Sigma Advisers LP bought a new position in Cocrystal Pharma in the third quarter valued at approximately $60,000. LPL Financial LLC grew its stake in Cocrystal Pharma by 12.2% in the fourth quarter. LPL Financial LLC now owns 200,250 shares of the company’s stock valued at $130,000 after purchasing an additional 21,750 shares in the last quarter. Finally, Citadel Advisors LLC bought a new position in Cocrystal Pharma in the second quarter valued at approximately $137,000. Hedge funds and other institutional investors own 15.43% of the company’s stock.

COCP has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Cocrystal Pharma in a report on Monday, March 14th. Noble Financial restated a “buy” rating and issued a $5.00 price target on shares of Cocrystal Pharma in a report on Thursday, May 12th.

About Cocrystal Pharma (Get Rating)

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections.

Recommended Stories

Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.